<DOC>
	<DOCNO>NCT00910845</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness botulinum toxin type A ( onabotulinumtoxinA ) treat patient idiopathic overactive bladder urinary incontinence .</brief_summary>
	<brief_title>Study Botulinum Toxin Type A Treatment Patients With Idiopathic Overactive Bladder With Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Symptoms OAB ( frequency/urgency ) urinary incontinence least 6 month Inadequate response limit side effect anticholinergic treatment OAB Overactive Bladder cause neurological condition Patient predominance stress incontinence History evidence pelvic urological abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>